Literature DB >> 6254187

The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans.

M de Brabander, F Aerts, J van Cutsem, H van den Bossche, M Borgers.   

Abstract

A system is described which allows the semi-quantitative investigation of the interaction between Candida albicans and leukocytes in culture with and without the addition of chemotherapeutic agents. Both polymorphonuclear leukocytes and macrophages avidly engulfed added yeast cells. However, they did not succeed in eradicating the fungus even when only 450 yeast cells were added to 3 X 10(6) leukocytes. This is probably due to several factors, including the decline in the functiontional capacity of the leukocytes with time in culture. The major way for the fungus to escape intracellular killing, however, seems to be the switch to the mycellial form in the presence of leukocytes. Engulfed yeasts produce germ tubes, grow out of the leukocytes and form hyphae which are much more resistant to the lytic action of the leukocytes. The leukocytes become necrotic through their interaction with the mycelia. Ketoconazole, a potent, orally active systemic antifungal agent inhibited the growth of C. albicans and completely suppressed the formation of mycelia in culture at very low concentrations (0.01 microgram ml-1). It was toxic to the leukocytes themselves only at 100 microgram ml-1. Addition of ketoconazole (10 (10-1.01 microgram ml-1) to mixed cultures of leukocytes and C. albicans allowed complete elimination of the fungus, probably because the leukocytes could easily remove the remaining yeast cells. The data show the usefulness of the system in the search for systemic antifungals and provide a possible explanation for the efficacy of ketoconazole in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254187     DOI: 10.1080/00362178085380351

Source DB:  PubMed          Journal:  Sabouraudia        ISSN: 0036-2174


  17 in total

1.  Acetate-mediated growth inhibition in sterol 14alpha-demethylation-deficient cells of Candida albicans.

Authors:  O Shimokawa; H Nakayama
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Sensitivity testing with ketoconazole in an assay containing Candida albicans, human polymorphonuclear leukocytes and serum.

Authors:  T M Bauer; W Kronsteiner; M Bassler; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

3.  Relationship between MIC and minimum sterol 14{alpha}-demethylation-inhibitory concentration as a factor in evaluating activities of azoles against various fungal species.

Authors:  Osamu Shimokawa; Masakazu Niimi; Ken Kikuchi; Mitsumasa Saito; Hideko Kajiwara; Shin-Ichi Yoshida
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 4.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

5.  Intermittent ketoconazole therapy of chronic mucocutaneous candidiasis in childhood.

Authors:  S Fanconi; R Seger; P Joller; C Issler; G Schär
Journal:  Eur J Pediatr       Date:  1982-11       Impact factor: 3.183

6.  Pharmacokinetics of ketoconazole in patients with neoplastic diseases.

Authors:  A W Maksymiuk; H B Levine; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

7.  Synergy of itraconazole with macrophages in killing Blastomyces dermatitidis.

Authors:  E Brummer; P R Bhagavathula; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes.

Authors:  G Raponi; M C Ghezzi; C Mancini; F Filadoro
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Increased sensitivity of Candida albicans cells accumulating 14 alpha-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents.

Authors:  O Shimokawa; H Nakayama
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  In vitro and in vivo activities of formycin B against Trypanosoma cruzi.

Authors:  R E McCabe; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.